Clinical trials
Peripheral Nervous System Diseases clinical trials
Below are recruiting peripheral nervous system diseases clinical trials, each written for real people, not researchers. We’re tracking 64 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05349006RecruitingPhase 3
Azathioprine for first attack in MOG antibody disease
This Phase 3 trial studies whether azathioprine can help prevent problems after a first attack of MOG antibody–related inflammation of the brain/spinal cord. It’s for adults with a recent first episode and confirmed MOG antibodies.
BordeauxAges 18 years+ - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07413341RecruitingPhase 1
Study of new drug TI-0032-III for hard-to-treat autoimmune diseases
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07390539RecruitingPhase 1
CAR T cells targeting B7-H3 for brain tumors
This trial tests a new type of immune therapy (CAR T cells) that targets a protein called B7-H3 found on some brain tumors. It is for children and young adults with certain brain or spinal cord tumors that have come back after standard treatment, and aims to see if the treatment is safe and effective.
Boston, MassachusettsAges 2–21 - NCT04684368RecruitingPhase 2
New treatment for children and young adults with a brain tumor
This trial tests a new treatment approach for a rare brain tumor called NGGCT. It aims to see if a different way of treating the tumor can be effective and safe for children and young adults.
Birmingham, AlabamaAges 3–29 - NCT07842835Recruiting
Biosample registry for primary CNS lymphoma
This study collects blood, cerebrospinal fluid, and tumor tissue samples over time from people with suspected or confirmed primary central nervous system lymphoma (PCNSL) in China. The goal is to build a large biobank to better understand the disease and improve future diagnosis and treatment.
Beijing, Beijing MunicipalityAges 18–100 - NCT06490822Recruiting
Skin study for frontotemporal lobe degeneration
This study looks at whether skin samples can help detect brain changes in people with frontotemporal lobe degeneration (a type of dementia) and related conditions. It compares skin from patients and healthy volunteers to find clues that might help with diagnosis.
NantesAges 50–75 - NCT07548723Enrolling by invitation
Nerve Stimulation Device Reliability Study
This study tests how reliably a small ear-stimulation device measures heart-rhythm patterns. Researchers want to see if the device gives consistent readings across multiple measurement sessions, which could help doctors monitor heart health in the future.
SinopAges 18–40 - NCT07482930Recruiting
Nerve stimulation and breathing test study in healthy adults
This study tests if a gentle nerve stimulation device placed on the ear can change how you breathe during a lung function test. It is only for healthy volunteers aged 18–40 who have no heart, lung, nerve, or mental health conditions.
SinopAges 18–40 - NCT07470151Recruiting
Study of EVM18001 for hard-to-treat autoimmune diseases
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
Wuhan, HubeiAges 18–70 - NCT07288840Enrolling by invitation
Exercise plan for heart recovery monitored by heart rate
This study tests a special exercise program for people with heart disease or heart failure. The goal is to see if the exercises can help improve how your heart responds to activity and daily life.
Leiria, Leiria DistrictAges 18 years+ - NCT07243470RecruitingPhase 1/Phase 2
Tarlatamab and temozolomide for brain tumors
This trial tests a new combination of two drugs (tarlatamab and temozolomide) for people with certain types of aggressive brain or central nervous system tumors that have come back or not responded to standard treatment. The hope is that this combination may work better against tumors that have a specific marker called DLL3.
AngersAges 12 years+ - NCT07185373RecruitingPhase 2/Phase 3
Newly diagnosed CNS lymphoma with orelabrutinib combination therapy
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
BeijingAges 18–75 - NCT07087002RecruitingPhase 1
GPC2-CAR T cells for children and young adults with relapsed medulloblastoma
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
Palo Alto, CaliforniaAges 1–30 - NCT06213636RecruitingPhase 1/Phase 2
New CAR T cells for resistant B-cell leukemia or lymphoma
This trial tests a new type of CAR T-cell therapy that targets two specific markers (CD19 and CD22) on cancer cells. It is for people ages 1 to 30 with hard-to-treat B-cell leukemia or lymphoma that has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 2–90 - NCT05474378RecruitingPhase 1
CAR T cell therapy for recurrent glioblastoma
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
Palo Alto, CaliforniaAges 18 years+ - NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT04276870RecruitingPhase 2
CD19 gene-modified cells for high-risk B-cell leukemia
This Phase 2 trial studies CD19 “redirected” cells made from your own blood to treat certain high-risk or relapsed B-cell acute lymphoblastic leukemia (B-ALL). It may help by targeting cancer cells that carry a protein called CD19.
Philadelphia, PennsylvaniaAges birth–29 years - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Birmingham, AlabamaAges 12 months–25 years - NCT07619885RecruitingPhase 1
Testing a New Blood Thinner Called CG-0255 in Healthy People
This study tests how a new blood-thinning medication (CG-0255) works in the body and compares it with Plavix, a common blood thinner. Researchers will measure how much of the drug enters your bloodstream and what effects it has on your blood clotting ability.
Miami, FloridaAges 18–55 - NCT06561048RecruitingPhase 3
Soquelitinib vs standard care for relapsed or refractory T-cell lymphoma
This trial compares a new drug, soquelitinib, with standard treatments for peripheral T-cell lymphoma that has come back or not responded to previous therapy. It may help people who have had one to three prior treatments and are looking for a new option.
Duarte, CaliforniaAges 18 years+ - NCT06316791RecruitingEarly Phase 1
CNCT19 CAR-T therapy for refractory autoimmune diseases
This early-phase study tests a new CAR-T cell therapy (CNCT19) for people with certain autoimmune diseases that have not responded to standard treatments. It targets a protein called CD19 on immune cells to help reset the immune system and reduce disease activity.
Zhengzhou, HenanAges 18–70
Hear when a new Peripheral Nervous System Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for peripheral nervous system diseases?
- Yes. Clin2 currently lists 64 recruiting peripheral nervous system diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peripheral nervous system diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peripheral nervous system diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.